BVT Bonus Zert SNW 30.12.2025/ DE000VC6A0V6 /
13/11/2024 10:31:44 | Var.-0.260 | Denaro12:31:12 | Lettera12:31:12 | Sottostante | Prezzo di esercizio | Expiration date | Tipo di opzione |
---|---|---|---|---|---|---|---|
109.950EUR | -0.24% | 109.800 Quantità in denaro: 5,600 |
109.840 Quantità in lettera: 5,600 |
SANOFI SA INHABER ... | - EUR | 30/12/2025 | Call |
GlobeNewswire
02/09
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to ...
GlobeNewswire
26/08
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...
GlobeNewswire
14/08
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
GlobeNewswire
13/08
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
12/08
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter ...
GlobeNewswire
08/08
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free sur...
GlobeNewswire
06/08
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D ...
GlobeNewswire
01/08
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
31/07
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2...
GlobeNewswire
25/07
Press Release: Online availability of Sanofi’s half-year financial report for 2024
GlobeNewswire
25/07
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
GlobeNewswire
24/07
US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold...
GlobeNewswire
18/07
Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, Accord...